Gag-Pol Processing During HIV-1 Virion Maturation: a Systems Biology Approach

Overview

Journal PLoS Comput Biol

Specialty Biology

Date 2013 Jun 12

PMID 23754941

Citations 30

Authors

Balazs Konnyu

S Kashif Sadiq

Tamas Turanyi

Rita Hirmondo

Barbara Muller

Hans-Georg Krausslich

Peter V Coveney

Viktor Muller

Affiliations

Soon will be listed here.

Abstract

Proteolytic processing of Gag and Gag-Pol polyproteins by the viral protease (PR) is crucial for the production of infectious HIV-1, and inhibitors of the viral PR are an integral part of current antiretroviral therapy. The process has several layers of complexity (multiple cleavage sites and substrates; multiple enzyme forms; PR auto-processing), which calls for a systems level approach to identify key vulnerabilities and optimal treatment strategies. Here we present the first full reaction kinetics model of proteolytic processing by HIV-1 PR, taking into account all canonical cleavage sites within Gag and Gag-Pol, intermediate products and enzyme forms, enzyme dimerization, the initial auto-cleavage of full-length Gag-Pol as well as self-cleavage of PR. The model allows us to identify the rate limiting step of virion maturation and the parameters with the strongest effect on maturation kinetics. Using the modelling framework, we predict interactions and compensatory potential between individual cleavage rates and drugs, characterize the time course of the process, explain the steep dose response curves associated with PR inhibitors and gain new insights into drug action. While the results of the model are subject to limitations arising from the simplifying assumptions used and from the uncertainties in the parameter estimates, the developed framework provides an extendable open-access platform to incorporate new data and hypotheses in the future.

Citing Articles

Modeling and Analysis of HIV-1 Pol Polyprotein as a Case Study for Predicting Large Polyprotein Structures.

Hao M, Imamichi T, Chang W Int J Mol Sci. 2024; 25(3).

PMID: 38339086 PMC: 10855158. DOI: 10.3390/ijms25031809.

Molecular dynamics simulations of HIV-1 matrix-membrane interactions at different stages of viral maturation.

Banerjee P, Qu K, Briggs J, Voth G Biophys J. 2024; 123(3):389-406.

PMID: 38196190 PMC: 10870173. DOI: 10.1016/j.bpj.2024.01.006.

The C-Terminal Domain of RNase H and the C-Terminus Amino Acid Residue Regulate Virus Release and Autoprocessing of a Defective HIV-1 Possessing M50I and V151I Changes in Integrase.

Imamichi T, Chen Q, Hao M, Chang W, Yang J Viruses. 2022; 14(12).

PMID: 36560691 PMC: 9788298. DOI: 10.3390/v14122687.

Sequence dependencies and biophysical features both govern cleavage of diverse cut-sites by HIV protease.

Samant N, Nachum G, Tsepal T, Bolon D Protein Sci. 2022; 31(7):e4366.

PMID: 35762719 PMC: 9207908. DOI: 10.1002/pro.4366.

Analyses of HIV proteases variants at the threshold of viability reveals relationships between processing efficiency and fitness.

Schneider-Nachum G, Flynn J, Mavor D, Schiffer C, Bolon D Virus Evol. 2022; 7(2):veab103.

PMID: 35299788 PMC: 8923237. DOI: 10.1093/ve/veab103.

References

de Marco A, Muller B, Glass B, Riches J, Krausslich H, Briggs J . Structural analysis of HIV-1 maturation using cryo-electron tomography. PLoS Pathog. 2010; 6(11):e1001215. PMC: 2999899. DOI: 10.1371/journal.ppat.1001215. View

Muller V, Maree A, de Boer R . Release of virus from lymphoid tissue affects human immunodeficiency virus type 1 and hepatitis C virus kinetics in the blood. J Virol. 2001; 75(6):2597-603. PMC: 115882. DOI: 10.1128/JVI.75.6.2597-2603.2001. View

Back D, Sekar V, Hoetelmans R . Darunavir: pharmacokinetics and drug interactions. Antivir Ther. 2008; 13(1):1-13. View

Di Marzo Veronese F, Copeland T, Devico A, Rahman R, Oroszlan S, Gallo R . Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV. Science. 1986; 231(4743):1289-91. DOI: 10.1126/science.2418504. View

Pettit S, Everitt L, Choudhury S, Dunn B, Kaplan A . Initial cleavage of the human immunodeficiency virus type 1 GagPol precursor by its activated protease occurs by an intramolecular mechanism. J Virol. 2004; 78(16):8477-85. PMC: 479095. DOI: 10.1128/JVI.78.16.8477-8485.2004. View

van Maarseveen N, Andersson D, Lepsik M, Fun A, Schipper P, De Jong D . Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity. Retrovirology. 2012; 9:29. PMC: 3349524. DOI: 10.1186/1742-4690-9-29. View

Anderson J, Schiffer C, Lee S, Swanstrom R . Viral protease inhibitors. Handb Exp Pharmacol. 2008; (189):85-110. PMC: 7120715. DOI: 10.1007/978-3-540-79086-0_4. View

Breuer S, Sepulveda H, Chen Y, Trotter J, Torbett B . A cleavage enzyme-cytometric bead array provides biochemical profiling of resistance mutations in HIV-1 Gag and protease. Biochemistry. 2011; 50(20):4371-81. PMC: 3159576. DOI: 10.1021/bi200031m. View

Wiegers K, RUTTER G, Kottler H, Tessmer U, Hohenberg H, Krausslich H . Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J Virol. 1998; 72(4):2846-54. PMC: 109729. DOI: 10.1128/JVI.72.4.2846-2854.1998. View

10.

Sedaghat A, Wilke C . Kinetics of the viral cycle influence pharmacodynamics of antiretroviral therapy. Biol Direct. 2011; 6:42. PMC: 3203257. DOI: 10.1186/1745-6150-6-42. View

11.

Briggs J, Wilk T, Welker R, Krausslich H, Fuller S . Structural organization of authentic, mature HIV-1 virions and cores. EMBO J. 2003; 22(7):1707-15. PMC: 152888. DOI: 10.1093/emboj/cdg143. View

12.

Adamson C, Freed E . Human immunodeficiency virus type 1 assembly, release, and maturation. Adv Pharmacol. 2007; 55:347-87. DOI: 10.1016/S1054-3589(07)55010-6. View

13.

Ramratnam B, Bonhoeffer S, Binley J, Hurley A, Zhang L, Mittler J . Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet. 1999; 354(9192):1782-5. DOI: 10.1016/S0140-6736(99)02035-8. View

14.

Gillespie D . Stochastic simulation of chemical kinetics. Annu Rev Phys Chem. 2006; 58:35-55. DOI: 10.1146/annurev.physchem.58.032806.104637. View

15.

Briggs J, Riches J, Glass B, Bartonova V, Zanetti G, Krausslich H . Structure and assembly of immature HIV. Proc Natl Acad Sci U S A. 2009; 106(27):11090-5. PMC: 2700151. DOI: 10.1073/pnas.0903535106. View

16.

Tozser J, Shulenin S, Kadas J, Boross P, Bagossi P, Copeland T . Human immunodeficiency virus type 1 capsid protein is a substrate of the retroviral proteinase while integrase is resistant toward proteolysis. Virology. 2003; 310(1):16-23. DOI: 10.1016/s0042-6822(03)00074-6. View

17.

Jolly C, Kashefi K, Hollinshead M, Sattentau Q . HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J Exp Med. 2004; 199(2):283-93. PMC: 2211771. DOI: 10.1084/jem.20030648. View

18.

Dierynck I, de Wit M, Gustin E, Keuleers I, Vandersmissen J, Hallenberger S . Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J Virol. 2007; 81(24):13845-51. PMC: 2168871. DOI: 10.1128/JVI.01184-07. View

19.

Pettit S, Lindquist J, Kaplan A, Swanstrom R . Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates. Retrovirology. 2005; 2:66. PMC: 1291402. DOI: 10.1186/1742-4690-2-66. View

20.

Muller B, Anders M, Akiyama H, Welsch S, Glass B, Nikovics K . HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity. J Biol Chem. 2009; 284(43):29692-703. PMC: 2785601. DOI: 10.1074/jbc.M109.027144. View